news
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
28 May 2014 | By Sanofi
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil)...
List view / Grid view
Sanofi
news
Sanofi appoints Dr. Anne C. Beal to the newly created position of Chief Patient Officer
31 March 2014 | By Sanofi
Appointment is a first for a Top 10 Biopharmaceutical Company...
news
Sanofi and UCB partner for breakthrough innovation in immune-mediated diseases
11 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
news
Sanofi’s Board of Directors propose appointment of Patrick Kron as new independent Director
6 March 2014 | By Sanofi
At its meeting held on March 5, 2014, the Board of Directors of Sanofi proposed the appointment of Patrick Kron as a new independent Director...
news
Sanofi celebrates 50th anniversary of France – China relations
27 January 2014 | By Sanofi
Sanofi announced its participation in the commemoration of the 50th anniversary of diplomatic relations between France and the People's Republic of China...
news
Sanofi and Fraunhofer-Gesellschaft announce the creation of a natural product center of excellence
15 January 2014 | By Sanofi
Goal is to identify novel active compounds to accelerate the discovery and development of new antibiotics...
news
Genzyme and Alnylam expand collaboration on rare genetic diseases
13 January 2014 | By Sanofi
Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates...
news
Sanofi to expand access to Clinical Trial Data
2 January 2014 | By Sanofi
“Sanofi has a history of contributing in this collective effort of sharing clinical trial data and results with researchers and patients with initiatives such as Project Data Sphere..."
news
Sanofi and Regeneron announce collaboration with American College of Cardiology for PCSK9 inhibitor clinical program
19 December 2013 | By Sanofi
Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment...
news
Sanofi announces new phase 3 results for investigational new insulin U300
3 December 2013 | By Sanofi
EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®...
news
Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
news
Sanofi discontinues clinical development of investigational JAK2 agent Fedratinib (SAR302503)
18 November 2013 | By Sanofi
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor...
news
Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
news
Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
news
Sanofi provides update on lixisenatide New Drug Application in U.S.
12 September 2013 | By Sanofi
Sanofi announced its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S...
